Knight Therapeutics advances chronic GvHD expansion strategy
Knight Therapeutics has announced the regulatory submission of Niktimvo (axatilimab) in Brazil for the treatment of chronic graft-versus-host disease (cGvHD),…
Analyst Comment
JPM26: Ypsomed commits to self-care delivery devices in new strategic plan
JPM26: Opus Genetics builds momentum in rare retinal gene therapy
JPM26: Butterfly Network aims to close the global medical imaging gap
JPM26: Rakuten Medical unveils transformative photoimmunotherapy platform
JPM26: ICU Medical hopeful to ‘get out of the woods’ soon
JPM26: Integra resets by fixing supply and riding reimbursement tailwinds
JPM26: Ambu strengthens growth outlook as single-use endoscopy adoption grows
